Will DANCAVAS be the most important screening trial in the last 50 years?

Area of Science:

• Cardiology
• Preventive Medicine
• Public Health

Background:

• Cardiovascular disease screening trials have historically struggled to demonstrate a significant reduction in all-cause mortality.
• The Danish Cardiovascular Screening trial (DANCAVAS) aimed to assess the impact of screening on mortality in men aged 65-74.

Purpose of the Study:

• To evaluate the effectiveness of cardiovascular screening in reducing all-cause mortality.
• To analyze subgroup differences and identify potential benefits of screening in specific age groups.
• To highlight the importance of coronary artery calcium scoring in cardiovascular risk assessment.

Main Methods:

• Randomized controlled trial design comparing screened versus unscreened men aged 65-74.
• Interim analysis of all-cause mortality as the primary outcome.
• Subgroup analysis focusing on younger participants (65-69 years old).

Main Results:

• The 5-year interim analysis did not show a statistically significant reduction in all-cause mortality (Hazard Ratio: 0.95, Confidence Interval: 0.90-1.00).
• A significant benefit was observed in the subgroup of men aged 65-69, with a lower hazard ratio for all-cause mortality (0.89, CI 0.83-0.96).
• A widening difference in outcomes between screened and unscreened groups suggests a potential long-term benefit.

Conclusions:

• While the overall trial did not meet statistical significance for all-cause mortality at the interim analysis, subgroup findings indicate a benefit in younger men.
• The trial is poised to become influential, emphasizing the critical role of coronary artery calcium scoring.
• Implementing coronary artery calcium scoring could be a key strategy for improving cardiovascular health and reducing mortality.